Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions

Background: Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder with interrelated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Methods: This article reviews the biological changes (genetic, molecular, and cellular) underlying AD and their correlation with the clinical syndrome. Results: Dementia associated with AD is related to the aberrant production, processing, and clearance of beta-amyloid and tau. Beta-amyloid deposition in brain follows a distinct spatial progression starting in the basal neocortex, spreading throughout the hippocampus, and eventually spreading to the rest of the cortex. The spread of tau pathology through neural networks leads to a distinct and consistent spatial progression of neurofibrillary tangles, beginning in the transentorhinal and hippocampal region and spreading superolaterally to the primary areas of the neocortex. Synaptic dysfunction and cell death is shown by progressive loss of cerebral metabolic rate for glucose and progressive brain atrophy. Decreases in synapse number in the dentate gyrus of the hippocampus correlate with declining cognitive function. Amyloid changes are detectable in cerebrospinal fluid and with amyloid imaging up to 20 years prior to the onset of symptoms. Structural atrophy may be detectable via magnetic resonance imaging up to 10 years before clinical signs appear. Conclusion: This review highlights the progression of biological changes underlying AD and their association with the clinical syndrome. Many changes occur before overt symptoms are evident and biomarkers provide a means to detect AD pathology even in patients without symptoms.

[1]  H. Stefánsson,et al.  Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease , 2015, Circulation.

[2]  L. Frölich,et al.  The metabolism hypothesis of Alzheimer’s disease: from the concept of central insulin resistance and associated consequences to insulin therapy , 2015, Journal of Neural Transmission.

[3]  A. Goate,et al.  Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis , 2015, Biological Psychiatry.

[4]  X. Wang,et al.  Polymorphism of the OLR1 3'UTR potential microRNA binding site and risk of Alzheimer's disease: a meta-analysis. , 2014, Genetics and molecular research : GMR.

[5]  B. Strooper,et al.  Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.

[6]  K. M. Deneen,et al.  Altered effective connectivity patterns of the default mode network in Alzheimer's disease: An fMRI study , 2014, Neuroscience Letters.

[7]  W. Lukiw,et al.  Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update , 2014, Front. Aging Neurosci..

[8]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[9]  D. Galimberti,et al.  Circulating miRNAs as potential biomarkers in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[10]  B. Ray,et al.  MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects* , 2013, The Journal of Biological Chemistry.

[11]  B. de Strooper,et al.  The composition of the γ-secretase complex defines its Aβ product profile , 2013, Molecular Neurodegeneration.

[12]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[13]  M. Mintun,et al.  Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer's disease , 2013, Alzheimer's & Dementia.

[14]  R. Singaraja TREM2: a new risk factor for Alzheimer's disease , 2013, Clinical genetics.

[15]  B. Hyman,et al.  Mechanisms of protein seeding in neurodegenerative diseases. , 2013, JAMA neurology.

[16]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[17]  Christine Van Broeckhoven,et al.  Genetic insights in Alzheimer's disease , 2013, The Lancet Neurology.

[18]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[19]  M. Daly,et al.  Variant TREM2 as risk factor for Alzheimer's disease. , 2013, The New England journal of medicine.

[20]  W. Jagust,et al.  Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. , 2013, Current Alzheimer research.

[21]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[22]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[23]  B. Ray,et al.  MicroRNA-153 Physiologically Inhibits Expression of Amyloid-β Precursor Protein in Cultured Human Fetal Brain Cells and Is Dysregulated in a Subset of Alzheimer Disease Patients* , 2012, The Journal of Biological Chemistry.

[24]  Stephen J. DeArmond,et al.  Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions , 2012, Proceedings of the National Academy of Sciences.

[25]  Hermona Soreq,et al.  Threshold-independent meta-analysis of Alzheimer's disease transcriptomes shows progressive changes in hippocampal functions, epigenetics and microRNA regulation. , 2012, Current Alzheimer research.

[26]  Mark Jenkinson,et al.  Structural MRI changes detectable up to ten years before clinical Alzheimer's disease , 2012, Neurobiology of Aging.

[27]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[28]  S. Robinson,et al.  Reactive astrocytes give neurons less support: implications for Alzheimer's disease , 2012, Neurobiology of Aging.

[29]  Menno P. Witter,et al.  Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.

[30]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[31]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[32]  P. Reddy,et al.  Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease , 2011, Brain Research.

[33]  P. Wong,et al.  Amyloid precursor protein processing and Alzheimer's disease. , 2011, Annual review of neuroscience.

[34]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[35]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[36]  P. Reddy,et al.  Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. , 2011, Biochimica et biophysica acta.

[37]  Michael D. Greicius,et al.  Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. , 2011, Cerebral cortex.

[38]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[39]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[40]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[41]  Huaxi Xu,et al.  APP processing in Alzheimer's disease , 2011, Molecular Brain.

[42]  Julie A. Harris,et al.  Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.

[43]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[44]  Hilkka Soininen,et al.  J-ADNI and selection of cognition measures , 2010, Alzheimer's & Dementia.

[45]  Harald Hampel,et al.  Biological markers of amyloid β-related mechanisms in Alzheimer's disease , 2010, Experimental Neurology.

[46]  B. Bendlin,et al.  Midlife Predictors of Alzheimer's Disease , 1999 .

[47]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[48]  K. Reymann,et al.  Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity , 2010, Proceedings of the National Academy of Sciences.

[49]  D. Teplow,et al.  Structure-neurotoxicity relationships of amyloid β-protein oligomers , 2009, Neuroscience Research.

[50]  R. Martins,et al.  Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease , 2009, Journal of neurochemistry.

[51]  Nick C. Fox,et al.  A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.

[52]  G. Stebbins,et al.  Diffusion Tensor Imaging in Alzheimer’s Disease and Mild Cognitive Impairment , 2009, Behavioural neurology.

[53]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[54]  Keith A. Johnson,et al.  Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.

[55]  Thomas Arendt,et al.  Synaptic degeneration in Alzheimer’s disease , 2009, Acta Neuropathologica.

[56]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease , 2009, Acta Neuropathologica.

[57]  Nick C Fox,et al.  Hippocampal atrophy rates in Alzheimer disease , 2009, Neurology.

[58]  P. Hajduk,et al.  Structural characterization of a soluble amyloid beta-peptide oligomer. , 2009, Biochemistry.

[59]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[60]  Rachel L. Mistur,et al.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[62]  H. Vinters,et al.  Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. , 2008, The American journal of pathology.

[63]  Daniel L. Rubin,et al.  Network Analysis of Intrinsic Functional Brain Connectivity in Alzheimer's Disease , 2008, PLoS Comput. Biol..

[64]  R O Weller,et al.  Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology , 2008, Neuropathology and applied neurobiology.

[65]  R. Carare,et al.  Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. , 2008, Brain pathology.

[66]  M. Beal,et al.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.

[67]  Kuncheng Li,et al.  Altered functional connectivity in early Alzheimer's disease: A resting‐state fMRI study , 2007, Human brain mapping.

[68]  F. Schmitt,et al.  Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment , 2007, Neurology.

[69]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[70]  Nick C Fox,et al.  Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study , 2006, The Lancet Neurology.

[71]  F. Schmitt,et al.  Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[72]  J. Götz,et al.  Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? , 2006, Journal of neurochemistry.

[73]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[74]  N. Bohnen,et al.  Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease , 2005, Neuroscience Letters.

[75]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[76]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[77]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[78]  M. Greicius,et al.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.

[79]  S. Hoyer,et al.  Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? , 2004, Journal of Neurology.

[80]  E. Mandelkow,et al.  Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses , 2003, Neurobiology of Aging.

[81]  Jean-Claude Baron,et al.  Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons , 2003, NeuroImage.

[82]  Michel Goedert,et al.  Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-β structure , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[83]  C. Haass,et al.  Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts , 2003, The Journal of cell biology.

[84]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[85]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[86]  S. Hoyer,et al.  The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update , 2002, Journal of Neural Transmission.

[87]  M. Kirkitadze,et al.  Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. , 2002 .

[88]  S. Laughlin,et al.  An Energy Budget for Signaling in the Grey Matter of the Brain , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[89]  S. Minoshima,et al.  In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.

[90]  H. Soininen,et al.  The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease , 1997, Neuroreport.

[91]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[92]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[93]  A. Crane,et al.  Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[94]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[95]  W J Schwartz,et al.  Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. , 1979, Science.

[96]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.